{"id":1949,"date":"2021-12-09T11:28:16","date_gmt":"2021-12-09T10:28:16","guid":{"rendered":"http:\/\/invivo.partners\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/"},"modified":"2021-12-09T11:36:40","modified_gmt":"2021-12-09T10:36:40","slug":"invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/","title":{"rendered":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#8217;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta."},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[],"class_list":["post-1949","post","type-post","status-publish","format-standard","hentry","category-noticias-ca"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#039;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners<\/title>\n<meta name=\"description\" content=\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#039;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#039;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#039;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-09T10:28:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-09T10:36:40+00:00\" \/>\n<meta name=\"author\" content=\"invivo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"invivo\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\"},\"author\":{\"name\":\"invivo\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\"},\"headline\":\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#8217;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.\",\"datePublished\":\"2021-12-09T10:28:16+00:00\",\"dateModified\":\"2021-12-09T10:36:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\"},\"wordCount\":41,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\",\"name\":\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2021-12-09T10:28:16+00:00\",\"dateModified\":\"2021-12-09T10:36:40+00:00\",\"description\":\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#8217;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\",\"name\":\"invivo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"caption\":\"invivo\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/invivocapital\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners","description":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/","og_locale":"ca_ES","og_type":"article","og_title":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners","og_description":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.","og_url":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/","og_site_name":"Invivo Partners","article_published_time":"2021-12-09T10:28:16+00:00","article_modified_time":"2021-12-09T10:36:40+00:00","author":"invivo","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"invivo"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/"},"author":{"name":"invivo","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789"},"headline":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#8217;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.","datePublished":"2021-12-09T10:28:16+00:00","dateModified":"2021-12-09T10:36:40+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/"},"wordCount":41,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/","url":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/","name":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta. - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2021-12-09T10:28:16+00:00","dateModified":"2021-12-09T10:36:40+00:00","description":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d'insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta.","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2021\/12\/09\/invivo-capital-invests-together-with-kurma-partners-v-bio-ventures-and-omnes-capital-in-corteria-pharmaceuticals-a-french-biotechnology-company-developing-novel-therapies-for-heart-failure-subpopula\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Invivo Capital inverteix, juntament amb Kurma Partners, V-Bio Ventures i Omnes Capital, a Corteria Pharmaceuticals, una empresa biotecnol\u00f2gica francesa que desenvolupa noves ter\u00e0pies per a subpoblacions d&#8217;insufici\u00e8ncia card\u00edaca amb una gran necessitat cl\u00ednica no coberta."}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789","name":"invivo","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","caption":"invivo"},"url":"https:\/\/invivo.partners\/ca\/author\/invivocapital\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=1949"}],"version-history":[{"count":3,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1949\/revisions"}],"predecessor-version":[{"id":1955,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1949\/revisions\/1955"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=1949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=1949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=1949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}